<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00841386</url>
  </required_header>
  <id_info>
    <org_study_id>101365</org_study_id>
    <nct_id>NCT00841386</nct_id>
  </id_info>
  <brief_title>Treatment of Keratoconus Using Collagen Cross-Linking</brief_title>
  <official_title>Treatment of Keratoconus Using Collagen Cross-Linking By Means of Topical Riboflavin and UV Light.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University at Buffalo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of collagen cross-linking in the
      cornea in halting the progression and possibly partially reversing the effects of
      keratoconus. Keratoconus is a progressive weakening in the cornea that causes irregular
      astigmatism and thinning of the cornea. The overall effect is reduction of vision, and in
      more advanced cases, scarring of the cornea that may lead to the need for corneal
      transplantation. Cross-linking has been shown increase the rigidity of the cornea. The
      patients would be treated once and then followed over 24 months. .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal is for two groups of approximately 66 patients to be included in the study. One eye
      from the first group will undergo treatment, while the second group of age matched
      individuals will serve as a control. It will be a prospective, randomized, blinded study.
      Each patient will be randomized at the beginning of enrollment in the study and will receive
      a randomization number. The following parameters will be followed: 1. Best corrected
      spectacle acuity (BCSA) 2. The steepest keratometry measurement (KMax) as measured by
      computerized corneal topography 3. Apical corneal thickness 4. Corneal mechanical resistance.
      These measurements will be repeated at 1 month, 3 months, 6 months, 12, 18, and 24 months
      following treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Spherical equivalent power of the cornea (Best spectacle refraction)</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>KMax: the maximum corneal curvature</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average corneal power of the cornea in the central 4 mm.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Corneal resistance factor.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal posterior surface elevation of the cornea.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apical corneal thickness.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial count.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Keratoconus</condition>
  <arm_group>
    <arm_group_label>Cross-linking treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical anesthesia (lidocaine jelly 2%) will be used. The central 9 mm of corneal epithelium will be removed cautiously with an Amoils brush. Riboflavin 0.1% solution will be applied (10 mg riboflavin-5-phosphate in 10 ml dextran T-500 20% solution, supplied in a sterile, single dose container) to the cornea every 2-3 minutes for 15 minutes and then every 5 minutes thereafter. The UV source will be from the CBM VEGA X-linker (CSO, Florence, Italy). A wavelength of 370 nm will be used to direct 5.4 J/cm2 to the area of cornea debrided for 30 minutes. The distance from the UV source to the cornea will be 1.5 to 5.4 cm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham treatment group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Topical anesthesia (lidocaine jelly 2%) will be used. Differing from the treatment group, no epithelium will be debrided, but instead, this step will be skipped and a 2% methylcellulose solution combined with 1% fluorescein dye will be applied to the cornea every 5 minutes for 30 minutes. The patient will be placed under the UV device, but instead of the UV light, the LED aiming beam will be applied for 30 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riboflavin-5-phosphate</intervention_name>
    <description>Riboflavin 0.1% (10 mg riboflavin-5-phosphate in 10 ml dextran T-500 20% solution, supplied in a sterile, single dose container) will be applied to the cornea every 2-3 minutes for 15 minutes prior to starting UV irradiation. The UV irradiation will be given in six 5 minute intervals. Additional riboflavin will be administered following each 5 minute UV treatment.</description>
    <arm_group_label>Cross-linking treatment</arm_group_label>
    <other_name>Ricrolin (SOOFT Italia Inc.)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sham cross-linking</intervention_name>
    <description>Topical anesthesia (lidocaine jelly 2%) will be used. Differing from the treatment group, no epithelium will be debrided, but instead, this step will be skipped and 2% methylcellulose solution with 1% sodium fluorescein will be applied to the cornea every 5 minutes for 15 minutes, and then every 5 minutes during the sham UV treatment. The patient will be placed under the UV device, and the aiming beam applied.</description>
    <arm_group_label>Sham treatment group</arm_group_label>
    <other_name>Goniosol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  no prior history of ocular surgery

          -  treatment eye must have a maximum corneal power of between 47 D and 60 diopters

          -  corneal thickness must be greater than 400 µ

          -  absence of corneal scarring

          -  patients must meet the diagnostic criteria for keratoconus, which include one or more
             of the following features:

               -  high myopia

               -  corneal ectasia as viewed by slit-lamp exam or measured by pachometry

               -  Vogt's striae

               -  topographic findings of superior flattening and inferior steepening of the cornea

               -  presence of Fleischer ring

        Exclusion Criteria:

          -  history of prior ocular surgery (history of contact lens use is not an exclusion
             criterion)

          -  average corneal power &gt; 60 D

          -  presence of corneal scarring

          -  corneal thickness 400 µ or less

          -  history of herpes simplex virus keratitis

          -  history of uveitis

          -  pre-existing glaucoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James J Reidy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>SUNY at Buffalo School of Medicine &amp; Biomedical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James J. Reidy, M.D.</last_name>
    <phone>716-881-7920</phone>
    <email>jreidymd@mac.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeanne Stutz</last_name>
    <phone>716-881-7920</phone>
    <email>jstutz@buffalo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fichte,Endl, &amp; Elmer EyeCare</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Grant, C.O.M.T.</last_name>
      <phone>716-564-2020</phone>
      <email>linda.grant@fichte.com</email>
    </contact>
    <contact_backup>
      <last_name>Michael Endl, M.D.</last_name>
      <phone>716-564-2020</phone>
      <email>mpderme@aol.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Endl, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas R Elmer, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ira G. Ross Eye Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James J Reidy, M.D.</last_name>
      <phone>716-881-7920</phone>
      <email>jreidymd@mac.com</email>
    </contact>
    <investigator>
      <last_name>James J Reidy, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandra L Everett, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nkcf.org</url>
    <description>National Keratoconus Foundation</description>
  </link>
  <results_reference>
    <citation>Natarajan R, Padmanabhan P, Guruswami S. Hydration behavior of porcine cornea crosslinked with riboflavin and ultraviolet A. J Cataract Refract Surg. 2007 Sep;33(9):1503.</citation>
    <PMID>17720054</PMID>
  </results_reference>
  <results_reference>
    <citation>Mazzotta C, Balestrazzi A, Traversi C, Baiocchi S, Caporossi T, Tommasi C, Caporossi A. Treatment of progressive keratoconus by riboflavin-UVA-induced cross-linking of corneal collagen: ultrastructural analysis by Heidelberg Retinal Tomograph II in vivo confocal microscopy in humans. Cornea. 2007 May;26(4):390-7.</citation>
    <PMID>17457184</PMID>
  </results_reference>
  <results_reference>
    <citation>Spoerl E, Mrochen M, Sliney D, Trokel S, Seiler T. Safety of UVA-riboflavin cross-linking of the cornea. Cornea. 2007 May;26(4):385-9. Review.</citation>
    <PMID>17457183</PMID>
  </results_reference>
  <results_reference>
    <citation>Mazzotta C, Traversi C, Baiocchi S, Sergio P, Caporossi T, Caporossi A. Conservative treatment of keratoconus by riboflavin-uva-induced cross-linking of corneal collagen: qualitative investigation. Eur J Ophthalmol. 2006 Jul-Aug;16(4):530-5.</citation>
    <PMID>16952090</PMID>
  </results_reference>
  <results_reference>
    <citation>Wollensak G. Crosslinking treatment of progressive keratoconus: new hope. Curr Opin Ophthalmol. 2006 Aug;17(4):356-60. Review.</citation>
    <PMID>16900027</PMID>
  </results_reference>
  <results_reference>
    <citation>Caporossi A, Baiocchi S, Mazzotta C, Traversi C, Caporossi T. Parasurgical therapy for keratoconus by riboflavin-ultraviolet type A rays induced cross-linking of corneal collagen: preliminary refractive results in an Italian study. J Cataract Refract Surg. 2006 May;32(5):837-45.</citation>
    <PMID>16765803</PMID>
  </results_reference>
  <results_reference>
    <citation>Kohlhaas M, Spoerl E, Schilde T, Unger G, Wittig C, Pillunat LE. Biomechanical evidence of the distribution of cross-links in corneas treated with riboflavin and ultraviolet A light. J Cataract Refract Surg. 2006 Feb;32(2):279-83.</citation>
    <PMID>16565005</PMID>
  </results_reference>
  <results_reference>
    <citation>Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus. Am J Ophthalmol. 2003 May;135(5):620-7.</citation>
    <PMID>12719068</PMID>
  </results_reference>
  <results_reference>
    <citation>Mencucci R, Mazzotta C, Rossi F, Ponchietti C, Pini R, Baiocchi S, Caporossi A, Menchini U. Riboflavin and ultraviolet A collagen crosslinking: in vivo thermographic analysis of the corneal surface. J Cataract Refract Surg. 2007 Jun;33(6):1005-8.</citation>
    <PMID>17531694</PMID>
  </results_reference>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2009</study_first_submitted>
  <study_first_submitted_qc>February 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2009</study_first_posted>
  <last_update_submitted>February 10, 2009</last_update_submitted>
  <last_update_submitted_qc>February 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2009</last_update_posted>
  <responsible_party>
    <name_title>James J. Reidy, M.D.</name_title>
    <organization>Department of Ophthalmology, SUNY at Buffalo</organization>
  </responsible_party>
  <keyword>Cornea</keyword>
  <keyword>Keratoconus</keyword>
  <keyword>Ectasia</keyword>
  <keyword>Riboflavin</keyword>
  <keyword>Collagen cross-linking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Riboflavin</mesh_term>
    <mesh_term>Flavin Mononucleotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

